T-cell receptor gene therapy for human papillomavirus-positive cancers
$227,059ZIAFY2013CANIH
Division Of Basic Sciences - Nci
Investigators
Linked publications, trials & patents
Paper 34116844Paper 33741731Paper 33558725Paper 31959727Paper 30646017Paper 29669936Paper 29528339Paper 29368612Paper 27037253Paper 26429982Paper 24329789Paper 24142051
Abstract
We have isolated a high-affinity HLA-A2-restricted TCR against the HPV-16 E6 oncoprotein. This was accomplished by identifying from the metastatic tumor of a patient with anal cancer a T cell clone against the 29-38 epitope of E6. The gene sequence of the TCR expressed by this clone was determined, and a retroviral expression vector encoding the TCR was generated. T cells transduced to express this TCR display high-avidity for the HPV-16 E6 29-38 epitope as well as specific recognition of HPV-16-positive tumor lines. A clinical trial testing adoptive transfer of autologous T cells transduced to express this TCR for the treatment of HPV-positive cancers is planned.
View original record on NIH RePORTER →